New Retina Radio
New Retina Radio

02.22.24

The State of Biosimilars: How We Got Here and What It Means for Practice

Two biosimilars are approved for use in retina by the US FDA—and more will be approved in the coming years. What exactly are biosimilars? What benefit might they provide? And how confident are retina specialist that biosimilars will deliver safe, high-quality care?  Moderator John Kitchens, MD, sits down with retina specialists Carl Awh, MD, and Firas Rahhal, MD, to answer these questions, and to ask whether the economic realities of biosimilars make them a good choice for modern retina practices.  This podcast is editorially independent, supported with advertising by Sandoz. 

View full description +

MORE EPISODES

11.13.25

AAO '25: GLP-1s and AMD, and Parity in Retina Care

Aleksandra Rachitskaya, MD; and Julia Haller, MD

11.10.25

Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLE

Rahul Khurana, MD; and Arshad Khanani, MD, MA

11.06.25

AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt Disease

Peter Kaiser, MD; and Michel Michaelides, MD

11.03.25

The Nuts and Bolts of GA Therapy: The Discussions Continue

Charles Wykoff, MD, PhD; Hasenin Al-khersan, MD; and Nakul Singh, MD

10.23.25

Late-Breaking Talks at AAO '25: Gene Therapy for RP and NPDR

Allen Ho, MD; and Charles Wykoff, MD, PhD

10.10.25

New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient Care

Niki Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD

10.09.25

The Nuts and Bolts of GA Therapy: The Opening Sessions

Charles Wykoff, MD, PhD; with Maryam Ghiassi, MD, MHS, and Matthew Cunningham, MD

10.02.25

Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring Vision

John Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD

Show More